Evidence map›Paper›PMID 40808941›Full record

ArticleFrontiers in immunology2025

Unveiling B7/CD28 family proteins in hepatocellular carcinoma: insights into communication and prognostic significance.

Yan Cai, Xiaodi Liu, Tao He, Yangming Xu, Shuxian Chen, Xianliang Tan, Shouchao Wei, Zimeng Wu, Liying Xiao, Baoming Luo

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan Cai *Department of Ultrasound, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Xiaodi Liu *Department of Ultrasound, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Tao HeDepartment of Ultrasound, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Yangming XuDepartment of Ultrasound, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Shuxian ChenDepartment of Ultrasound, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Xianliang TanDepartment of Ultrasound, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Shouchao WeiDepartment of Ultrasound, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Zimeng WuDepartment of Ultrasound, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Liying XiaoDepartment of Ultrasound, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Baoming LuoDepartment of Ultrasound, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immunotherapy has made remarkable achievements in cancer treatment, but it still faces the challenge of limited response rates in liver cancer therapy. Although there has been extensive research on the role of programmed cell death-ligand 1 (PD-L1) in hepatocellular carcinoma (HCC), our understanding of the effects of other inhibitory B7/CD28 family members is still limited despite advancements in prognostic tools, more specific, accurate, and robust biomarkers are required to improve HCC patient prognoses. Methods: We acquired the single-cell sequencing data from relevant literature and selected 42 liver tissue samples, including 89,246 cells from HCC patients, to investigate the expression, localization, and intercellular communications of the B7/CD28 family in HCC. Within the Cancer Genome Atlas dataset, we utilized Lasso and Cox regression analyses to develop a risk model for identifying the most pertinent B7/CD28 family proteins associated with prognosis. Subsequently, we conducted a retrospective analysis of 94 HCC patients who underwent hepatectomy at our institution and determined the prognostic significance of this malignancy. Results: Based on the single-cell RNA sequencing data, we have delineated various members of the B7/CD28 family and their corresponding receptors. We have elucidated their distribution on tumor cells and immune cells, revealing active intercellular communications among tumor cells, fibroblasts, and epithelial cells. Through the implementation of Lasso, we have pinpointed a significant correlation between the B7H3 molecule and prognosis. Leveraging multiplex immunofluorescence, we were able to discern three distinct patterns of B7H3 expression-tumor-associated, stroma-associated, and a hybrid form encompassing both. Notably, the presence of B7H3 in the stroma exhibited the most robust correlation with prognosis. Furthermore, the efficacy of our prognostic signature was validated through clinicopathological analyses conducted at our institution. Conclusions: In conclusion, the B7/CD28 family plays an active role in the tumor immune microenvironment and cellular communication. B7H3 could serve as an indicator for predicting the outcome of HCC. Additional investigation is required to validate these discoveries in future groups of individuals and assess their viability as therapies guided by biomarkers.

Indexed as

B7-1 AntigenB7 AntigensCarcinoma, HepatocellularCD28 AntigensLiver NeoplasmsAgedBiomarkers, TumorCell CommunicationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisRetrospective StudiesSingle-Cell AnalysisB7-1 AntigenB7 AntigensBiomarkers, TumorCD28 AntigensB7/CD28 family membersB7H3hepatocellular carcinoma (HCC)immunotherapyinhibitory B7 family memberssingle-cell RNA sequencingtumor immune environment

Identifiers

PMID40808941
PMCPMC12343519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.